Abstract:La catatonie est un syndrome clinique fréquent et pourtant méconnu. Décrite précisément par le psychiatre allemand Karl Kahlbaum à la fin du xixe siècle, la catatonie a connu certains rebondissements nosologiques. Rattachée à la schizophrénie par Emil Kraepelin puis par Eugen Bleuler, il a fallu attendre le milieu du xixe siècle pour reconnaître des catatonies en lien avec d’autres étiologies, notamment des affections somatiques. Ce changement de paradigme a permis de redécouvrir ce syndrome, d’en dessiner une prise en charge et de tenter d’en comprendre l’origine. D’un point de vue diagnostique, nous verrons que quelques signes cardinaux peuvent être retenus : inhibition et rigidité, stéréotypies, agitation sans but, négativisme et ambivalence. Le traitement de la catatonie doit être double : soulager le symptôme, c’est-à-dire lever l’état catatonique, et traiter la cause. Parmi les traitements symptomatiques, certaines benzodiazépines (notamment le lorazépam) et le zolpidem sont efficaces dans la majeure partie des cas et constituent un test diagnostique. En cas d’échec, l’électroconvulsivothérapie reste le traitement de référence en seconde ligne. Concernant la cause de la catatonie, on distingue les affections psychiatriques : les troubles de l’humeur en premier lieu, la schizophrénie, mais aussi l’autisme et la catatonie périodique, et également de très nombreuses causes organiques parmi lesquelles nous soulignerons la place de l’encéphalite à anticorps anti-NMDAR (récepteur N-Méthyl-D-Aspartate du glutamate). Le traitement de la cause doit être entrepris au plus vite et parallèlement au traitement de l’état catatonique, à l’exception des neuroleptiques qui risquent d’aggraver la catatonie s’ils sont administrés trop tôt. La catatonie correspondrait au niveau cérébral à un dysfonctionnement des circuits impliqués dans le mouvement volontaire, en réaction à la peur, le plus souvent sous forme stuporeuse mais parfois sous forme furieuse. Le cortex orbitofrontal latéral, en défaut dans la catatonie, et porteur de récepteurs GABA-A, serait fortement impliqué dans cette réaction primitive qu’il a pour rôle d’inhiber par interaction avec le cortex orbitofrontal médian et l’amygdale.Catatonia is a frequent but unrecognized syndrome. Described in the late nineteenth century by the German psychiatrist Karl Kahlbaum, catatonia has experienced some nosological twists including the attachment to schizophrenia by Emil Kraepelin and Eugen Bleuler. It was not until the mid-nineteenth century that clinicians recognize catatonia related to other etiologies including somatic ones. This paradigm shift has helped to rediscover this syndrome, to find a treatment algorithm and try to understand its pathophysiology. From a diagnostic point of view, we will see that a few cardinal signs may be retained: inhibition and rigidity, stereotypies, aimless agitation, negativity and ambivalence. The treatment of catatonia must be twofold: to relieve the catatonic state, and to treat the cause. Among symptomatic treatments, some benzodiazepines (such as lorazepam) and zolpidem are generally very effective and provide a diagnostic test. If that fails, electroconvulsive therapy is the main second line treatment. Regarding the cause of catatonia, one should distinguish psychiatric disorders: mood disorders, schizophrenia, autism and periodic catatonia; and numerous organic causes among which we will highlight anti-NMDAR (N-Methyl-D-aspartate glutamate receptor) encephalitis. Treating the cause should be undertaken as quickly as possible in parallel with the treatment of the catatonic state, except for neuroleptics which may worsen catatonia if administered early. Catatonia corresponds to a dysfunction of the circuits involved in voluntary movement in response to fear, most often in the form of stupor but sometimes in a furious form. The lateral orbitofrontal cortex, in default in catatonia, and carrier of GABA-A receptors, would be heavily involved in this primitive reaction which it should inhibit by interaction with the median orbitofrontal cortex and the amygdala.

Psychiatric phenotype in neurodevelopmental myoclonus-dystonia is underpinned by abnormality of cerebellar modulation on the cerebral cortex

Microstructure of the cerebellum and its afferent pathways underpins dystonia in myoclonus dystonia

Association of abnormal explicit sense of agency with cerebellar impairment in myoclonus-dystonia

Natural history of SGCE‐associated myoclonus dystonia in children and adolescents

Unravelling the impact of frontal lobe impairment for social dysfunction in myotonic dystrophy type 1

Altered Cerebello‐Motor Network in Familial Cortical Myoclonic Tremor with Epilepsy Type 1

Clinical and neurophysiological features of familial cortical myoclonic tremor with epilepsy.

Isolation of Distinct Networks Driving Action and Cognition in Psychomotor Processes

Multimodal neuroimaging to characterize symptom-specific networks in movement disorders

Genetic Diversity and Expanded Phenotypes in Dystonia: Insights from Large-Scale Exome Sequencing

Movement disorder phenotype in CTNNB1-syndrome: A complex but recognizable phenomenology

Motor system hyperconnectivity in juvenile myoclonic epilepsy: a cognitive functional magnetic resonance imaging study

Neuropsychiatric phenotypes in functional movement disorder

Moving across disorders: A cross-sectional study of cognition in early onset ataxia and dystonia

Behaviour-correlated profiles of cerebellar-cerebral functional connectivity observed in independent neurodevelopmental disorder cohorts

Striato-pallidal oscillatory connectivity correlates with symptom severity in dystonia patients

Movement Disorders Associated with Neuroleptics. the Curaçao Extrapyramidal Syndromes Study: I–III

Clinical and Neuroimaging Features of Dyssynergia Cerebellaris Myocionica in a Chinese Family

CHD8-related disorders redefined: an expanding spectrum of dystonic phenotypes

Altered dynamic functional connectivity of motor cerebellum with sensorimotor network and default mode network in juvenile myoclonic epilepsy

Relationship between transcranial magnetic stimulation markers of motor control and clinical recovery in obsessive compulsive disorder/Gilles de la Tourette syndrome: a proof of concept case study